Petros Stock Based Compensation To Revenue from 2010 to 2024
| PTPI Stock | USD 0.27 0.01 3.85% |
Stock Based Compensation To Revenue | First Reported 2010-12-31 | Previous Quarter 0.0716596 | Current Value 0.0681 | Quarterly Volatility 0.03605606 |
Check Petros Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Petros Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Expense of 509.3 K, Income Tax Expense of 5.9 B or Tax Provision of 0.0, as well as many indicators such as Price To Sales Ratio of 0.5, Dividend Yield of 145 or PTB Ratio of 0.33. Petros financial statements analysis is a perfect complement when working with Petros Pharmaceuticals Valuation or Volatility modules.
Petros | Stock Based Compensation To Revenue |
Latest Petros Pharmaceuticals' Stock Based Compensation To Revenue Growth Pattern
Below is the plot of the Stock Based Compensation To Revenue of Petros Pharmaceuticals over the last few years. It is a metric that compares the total value of stock-based compensation granted by a company to its total revenue, indicating how much of the revenue is used to compensate employees with stock options or awards. Petros Pharmaceuticals' Stock Based Compensation To Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Petros Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Stock Based Compensation To Revenue | 10 Years Trend |
|
Stock Based Compensation To Revenue |
| Timeline |
Petros Stock Based Compensation To Revenue Regression Statistics
| Arithmetic Mean | 0.16 | |
| Geometric Mean | 0.15 | |
| Coefficient Of Variation | 23.07 | |
| Mean Deviation | 0.02 | |
| Median | 0.17 | |
| Standard Deviation | 0.04 | |
| Sample Variance | 0 | |
| Range | 0.1313 | |
| R-Value | (0.49) | |
| Mean Square Error | 0 | |
| R-Squared | 0.24 | |
| Significance | 0.06 | |
| Slope | (0) | |
| Total Sum of Squares | 0.02 |
Petros Stock Based Compensation To Revenue History
About Petros Pharmaceuticals Financial Statements
Investors use fundamental indicators, such as Petros Pharmaceuticals' Stock Based Compensation To Revenue, to determine how well the company is positioned to perform in the future. Although Petros Pharmaceuticals' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
| Last Reported | Projected for Next Year | ||
| Stock Based Compensation To Revenue | 0.07 | 0.07 |
Currently Active Assets on Macroaxis
When determining whether Petros Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Petros Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Petros Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Petros Pharmaceuticals Stock:Check out the analysis of Petros Pharmaceuticals Correlation against competitors. For more detail on how to invest in Petros Stock please use our How to Invest in Petros Pharmaceuticals guide.You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Petros Pharmaceuticals. If investors know Petros will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Petros Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.80) | Revenue Per Share 0.99 | Quarterly Revenue Growth (0.29) | Return On Assets (0.31) | Return On Equity (0.64) |
The market value of Petros Pharmaceuticals is measured differently than its book value, which is the value of Petros that is recorded on the company's balance sheet. Investors also form their own opinion of Petros Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Petros Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Petros Pharmaceuticals' market value can be influenced by many factors that don't directly affect Petros Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Petros Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Petros Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Petros Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.